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ABSTRACT 
Objectives: To evaluate prevalence of ceftazidime-resistant K/eb- 
siella pneumoniae (CRKP) in the pediatric oncology unit of Uni- 
versity Hospital, Kuala, Lumpur, and to identify differences 
between febrile neutropenic pediatric patients with CRKP and 
ceftazidime-sensitive K. pneumoniae (CSKP) bacteremia. 
Materials and Methods: Febrile neutropenic patients treated 
between January 1996 and December 1997 at the pediatric 
oncology unit of University Hospital, Kuala Lumpur, were 
prospectively studied. Empirical antibiotic therapy consisted of 
ceftazidime and amikacin. Those who developed I<. pneumo- 
niae bacteremia were identified, and clinical features analyzed. 
Ceftazidime-resistance was documented via disk-diffusion test- 
ing. Production of extended-spectrum beta-lactamase (ESBL) 
was inferred on the basis of synergy between ceftazidime and 
amoxicillin-clavulanic acid. The different features between the 
two groups and variables associated with the development of 
CRKP bacteremia were analyzed using chi-square and t-tests 
and calculation of odds ratios. A multivariate analysis was used 
to identify independent factors for CRKP development. 
Results: Ceftazidime-resistance was seen in 51.6% of all K. 
pneumoniae isolates, and all these isolates were inferred to be 
ESBL producers. All isolates were sensitive to imipenem. Sus- 
ceptibility to gentamicin was 90.5%. The mean continuous hos- 
pital stay prior to the detection of bacteremia was 13.7 days 
overall, but significantly longer in the CRKP group (21.9 d) com- 
pared to the CSKP group (4.3 d) (P = 0.003). Children with 
CRKP were more likely to have received antibiotics in the 2 
weeks prior to detection of bacteremia (87.5% of cases) than 
the CSKP group (20.0% of cases) (P = 0.0008). Sepsis-related 
mortality was higher in those with CRKP (50.0%) than in the 
CSKP group (13.3%) (P = 0.02). Patients who did not receive 
CRKP-directed antibiotics within 48 hours of admission were 
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more likely to have a fatal outcome than those who did 
(P = 0.009). Logistic regression analysis identified use of third- 
generation cephalosporins 2 weeks prior to presentation and 
a hospital stay of 2 weeks or more as independent risk factors 
for development of CRKP. 
Conclusions: More than half of total K. pneumoniae isolated 
from blood cultures in the unit were ceftazidime-resistant. Chil- 
dren with febrile neutropenia with prolonged hospital stay and 
recent prior antibiotic exposure are at high risk of developing 
CRKP bacteremia. Mortality was significantly higher in this 
group. Early commencement of appropriate antibiotics (e.g., 
imipenem with or without gentamicin), according to suscepti- 
bility study results, may be beneficial in such circumstances, 
Key Words: ceffazidime-resistance, extended-spectrum beta- 
lacfamase, Klebsiella pneumoniae 
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Gram-negative bacterial infections are a major cause of 
morbidity and mortality in immunocompromised 
patients. A surveillance study at the pediatric oncology 
unit of the University Hospital in Kuala Lumpur, one of 
three main pediatric cancer centers in Malaysia, has 
shown that gram-negative bacteria form the majority of 
isolates in the etiology of bacteremia in this group of 
patients.’ Klebsiella pneumoniae has consistently been 
the most commonly isolated gram-negative bacteria, 
accounting for up to 20% of blood-culture isolates yearly. 
Since 1990, ceftaaidime and amikacin have been used as 
empirical therapy for febrile neutropenia in the unit. This 
combination also has been reported to be highly effica- 
cious in a trial conducted by the European Organization 
for Research and Treatment of Cancer (EORTC) in the 
treatment of febrile neutropenia.’ However, since the mid- 
1980s transferable plasmid-mediated resistance to third- 
generation cephalosporins in Klebsiella has been 
reported in Europe, 3-5 the United States6x7 Asia,G and 
Africa.8 This report highlights features that are associated 
with ceftazidime-resistant K. pneumoniae (CRKP) bac- 
teremia seen in these patients, in an attempt to identify 
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factors that may lead to the development of this often 
multiresistant and fatal organism. 
PATIENTS AND METHODS 
Patients 
Blood cultures were performed for all pediatric patients 
with neutropenia (aged 12 y and younger and having an 
absolute neutrophil count below 1 .O X 109/L) who devel- 
oped sign&ant fever (i.e., a single temperature of 38.5”~ 
or sustained axillary temperature of 38.O”C) for more 
than 2 hours. Blood was taken from a peripheral vein 
unless the patient had a central venous catheter, in which 
case blood would be obtained from the catheter. 
Microbiologic Methods 
One to 3 mL of blood was inoculated into Bactec Peds 
Plus vials and 5 mL into Bactec Plus anaerobic vials (Bec- 
ton-Dickinson Microbiology Systems, Maryland, USA). 
These cultures were processed in the microbiology lab- 
oratory, using an automated Bactec 9240 (Becton-Dick- 
inson Microbiology Systems) continuous monitoring 
system, using a 5-day protocol. Positive vials were sub- 
cultured, and isolates were identified by standard bacte- 
riologic methods. Susceptibility testing of the isolates was 
carried out using the Kirby-Bauer disk diffusion method 
on Mueller-Hinton agar, and zone diameters were inter- 
preted according to the National Committee for Clinical 
Laboratory Standards (NCCLS). Ceftazidime resistance 
was defined as a zone of inhibition less than 15 mm, sus- 
ceptibility as greater than 17 mm, and intermediate sus- 
ceptibility as 15 to 17 mm. Isolates with intermediate 
sensitivity were included in the CRKP group in this analy- 
sis. Other cephalosporins tested for included cefuroxime, 
ceftriaxone, cefoperazone, and cefotaxime, but not 
cefepime, cefoxitin, or cefotetan. All isolates also were 
tested for imipenem and ciprofloxacin sensitivity. How- 
ever, isolates were not tested for meropenem suscepti- 
bility, as this antibiotic was not available during the study 
period. Production of extended-spectrum beta-lactamase 
(ESBL) was inferred on the basis of a positive synergy 
test between ceftazidime and amoxicillin-clavulanic acid 
on double-disk diffusion testing. Criteria for synergy 
between amoxicillin-clavulanate and ceftazidime were 
according to methods described elsewhere.9 Resistance 
to ceftazidime was used as a marker of resistance to all 
third-generation cephalosporins. 
Clinical Data 
The following clinical data were obtained from the charts 
of all pediatric patients who had K.pneumoniae isolated 
from blood culture samples between January 1996 and 
December 1997: underlying diagnosis, use of co-trimox- 
azole prophylaxis, duration of continuous hospital stay, 
procedures undergone, types and duration of antibiotics 
prescribed prior to detection of bacteremia, and outcome. 
Statistical Analysis 
Univariate tests to determine associations between devel- 
opment of CRKP and pre-sepsis variables were performed 
using chi-square tests for categorical variables (e.g., prior 
use of antibiotics), and t-tests for continuous variables 
(e.g., duration of hospital stay). Strength of association 
was determined by calculating odds ratio (OR) and 95% 
confidence intervals (95% CI) around the ratio. Signifi- 
cance of odds ratio was calculated using the Wald test. 
Logistic regression analysis was used to identify variables 
as independent risk factors for the development of CRKF? 
SPSS for WindowsTM, version 6.0 (SPSS Inc., New York), 
was used for all statistical analyses. 
RESULTS 
Epidemiology 
From January 1996 to December 1997, 31 consecutive 
episodes of K. pneumoniae bacteremia occurred in 29 
children, representing 44% of all gram-negative bacteria 
isolated from blood cultures in the pediatric oncology 
unit of the University Hospital in Kuala Lumpur. Mean 
age at presentation was 76.9 months (range, 7-156 
months); 16 patients were male and 13 female. Underly- 
ing diseases were leukemia (n = IS), lymphoma (n = 4) 
neuroblastoma (n = 2>, osteosarcoma (n = l), rhab- 
domyosarcoma (n = l), and severe aplastic anemia 
(n = 3). Only three patients had in-dwelling central venous 
catheters. All patients had an absolute neutrophil count 
of less than 1.0 X 109/I. at presentation. The mean dura- 
tion of hospital stay prior to detection of bacteremia was 
13.7 days overall but significantly longer in the CRKP 
group (21.9 d) compared to the ceftazidime-sensitive 
group (4.3 d) (P = 0.003). A hospital stay of 2 weeks or 
more was noted in 14 patients and was significantly asso- 
ciated with the development of CRKP (OR = 19.5; 95% 
CI = 126.5) (P = 0.002). No significant difference was 
found in terms of invasive procedures (e.g., multiple 
venepunctures, intrathecal administration of chemother- 
apy, catheterization) between the two groups. Some of 
these features are summarized in Table 1. 
Microbiology 
Sixteen isolates (5 1.6%) showed resistance to ceftazidime 
by disk-diffusion susceptibility testing. Resistance to 
amikacin was 54.8% overall but was higher in the CRKP 
group (92%) than in the ceftazidime-sensitive isolates 
(14%). Twenty-one isolates were tested for gentamicin sen- 
sitivity and two (9.5%) were resistant. All CRKP isolates 
were inferred to be ESBL producers on the basis of a pos- 
itive synergy test between ceftazidime and amoxicillin- 
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Table 1. Univariate Analysis of Clinical Features of 31 Cases of 
Klebsiella pneumoniae Bacteremia 
Features 
CRKP Group CSKP Group Significance 
n = 76 (700%) n = 75 (7OO%j (P-Value) 
Hematologic 
malignancy 12 (75.0) IO (66.6) NS 
Hospital stay longer 
than 2 weeks prior 
to bacteremia 12 (85.7) 2 (14.3) 0.005 
Invasive procedure 
or chemotherapy * 13 (81.3) 10 (66.6) NS 
Prior antibiotic 
therapy+ 14 (87.5) 3 (20.0) 0.0002 
Use of prophylactic 
co-trimoxazole 5 (31.3) 8 (53.3) NS 
Sepsis-related mortality 8 (50.0) 2 (13.3) 0. 02 
*Underwent invasive procedure or received chemotherapy within -1 week prior 
to detection of bacteremia; +received broad-spectrum or third-generation 
cephalosporin antibiotics within 2 weeks prior to detection of bacteremia. 
NS = not significant. 
clavulanic acid on double-disk diffusion testing. All 3 1 iso- 
lates of K. pneumoniae were sensitive to imipenem. 
Another potentially useful antibiotic was ciprofloxacin, 
to which only 4 of 31 (13%) isolates showed resistance. 
The newer cephalosporins (e.g., cefepime, cefoxitin, and 
cefotetan) are not easily available in the hospital and, thus, 
were not included in routine susceptibility studies. 
Previous Antibiotic Therapy 
During the study period, empirical antibiotic therapy in 
the unit for febrile neutropenia consisted of ceftazidime 
and amikacin. Cloxacillin was added-on in patients with 
in-dwelling central venous catheters. Thirteen patients 
were taking co-trimoxazole for Pneumocystis carinii 
pneumonia. However, this was not significantly associ- 
ated with the development of CRKP (P = 0.13). Children 
with CRKP were more likely to have received broad-spec- 
trum antibiotics in the 2 weeks prior to detection of bac- 
teremia (87.5% of cases) than the CSKP group (20.0% of 
cases) (OR = 28.0; 95% CI = 4.0-194.5) (P = 0.0008). Of 
the 14 patients with CRKP who had received prior anti- 
biotic therapy, 11 had received ceftazidime and 3 ceftri- 
axone. By means of logistic regression analysis, using 
CRKP isolation as the dependent variable with adjust- 
ment for variables statistically significant in the univari- 
ate analysis, a hospital stay of 2 weeks or longer (OR = 
14.9; 95% CI = 2.3-99.6) (P = 0.02) and use of third-gen- 
eration cephalosporins within 2 weeks prior to presen- 
tation (OR = 11.1; 95% CI = 1.3-95.2) (IP = 0.03) 
remained significantly associated with CRKP blood infec- 
tion in the study group. 
Evidence suggests that ESBL-producing strains may 
be endemic in nursing homes, where there usually are 
groups of chronically debilitated patients who may serve 
as an ESBL reservoir in a community.1o However, once 
resident in a ward or hospital, ESBL-producing organisms 
are difficult to eradicate, because this organism can col- 
onize the gastrointestinal tract of patients. The fact that 
CRKP was isolated year-round in the study may be indi- 
rect evidence of colonization of the patients by this 
organism, forming a reservoir of infection. This is wors- 
ened by the fmding that the genes encoding for ESBLs can 
be transferred between strains and other bacterial 
species, causing infection to the host when defences are 
weak, or being nosocomially transmitted to other 
immunocompromised patients.” Therefore, it is not sur- 
prising that patients who developed CRKP bacteremia 
had had a prolonged duration of hospitalization com- 
pared to those who did not develop CRKP bacteremia. 
This concurs with previous studies in which coloniza- 
tion and infection by ESBL-producing Enterobacteriaceae 
have been associated with lengthy hospitalization, espe- 
cially in intensive care or oncology units.10,12 
Ceftazidime-resistant K. pneumoniae has been iso- 
lated in the study unit since 1990,l and there has been a 
steady increase, albeit plateauing at about 50% in the past 
2 years, in its incidence since then (Table 2). This is much 
higher than the rate of ceftazidime-resistant KZebsieZZa of 
16.6% found in a recent nationwide survey of six major 
hospitals.13 The extensive use of ceftazidime may have 
played a large role in the development and increasing 
incidence of CRKP in the study unit. The role of wide- 
spread ceftazidime use in the development of CRKP pre- 
Therapy and Outcome 
Sepsis-related mortality was higher in those with CRKP viously has been reported where an outbreak of 
(S/l6 patients, 50.0%) than in the CSKP group (2/15 ceftazidime-resistant gram-negative bacillary infections 
patients, 13.3%),(OR = 6.5; 95% CI = 1.1-38.6) (P = 0.02). arose a year after a policy of empirical ceftazidime 
Patients who did not receive appropriate antibiotics 
within 48 hours of presentation were more likely to have 
a fatal outcome (OR = 9.0; 95% CI = 1.5-52.3) (P = 0.009). 
Six patients with CRKP received imipenem within 48 
hours of presentation; only one (16.6%) death occurred 
in this group. One patient in the CRKP sepsis was given 
ciprofloxacin as second-line antibiotic therapy and 
survived. 
DISCUSSION 
Despite advances in the treatment of childhood malig- 
nancy, infection remains a major cause of morbidity and 
mortality. Klebsiella spp resistant to the extended and 
broad-spectrum cephalosporins by the production of 
ESBLs have been isolated sporadically since the early 
1980s. They have since become well-established in many 
hospitals worldwide. They also may be resistant to the flu- 
oroquinolones but usually are susceptible to the car- 
bepenems, as seen in the authors’ experience. 
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Table 2. Trend of Resistance of Klebsiella pneumoniae 
Isolated from Blood Cultures to Ceftazidime and Arnikacin in the 
Pediatric Oncology Unit of University Hospital, Kuala Lumpur 
Percentage Resistant to 
Year Number of isolates Ceftazidime (%) Amikacin (%) 
1990 19 26 21 
1991 23 39 26 
1992 20 50 50 
1993 15 46 46 
1994 20 55 50 
1995 20 45 40 
1996 13 46 54 
1997 18 52 54 
monotherapy for febrile neutropenia was practiced. l4 
Withholding use of ceftazidime temporarily was associ- 
ated with eradication of this outbreak. 
Ceftazidime-resistant K.pneumoniae are usually sus- 
ceptible to the carbepenems. From microbiologic sur- 
veillance during the study period, imipenem resistance 
was not found in any of the CRKP isolates and thus, is use- 
ful in the treatment of CRKP infections. A recent survey 
measuring in vitro susceptibility of 28 random strains of 
ESBL-producing CRKP isolated from various wards in Uni- 
versity Hospital found imipenem to have the highest 
degree of activity, with 100% of the strains being fully 
susceptible at a breakpoint of less than 4 mg/L, followed 
by cefepime, with 79% of the strains being fully suscep- 
tible at a breakpoint of less than 8 mg/L.lj 
Although this study is limited by its low statistical 
power, as reflected by wide confidence interval values, 
owing to the small sample size, several management 
strategies may be useful. Mortality was signillcantly higher 
in patients with CRKP (P = 0.02); therefore, early com- 
mencement of imipenem may be useful in children at 
high risk of developing CFXP septicemia, that is, those 
with a prolonged duration of hospital stay and who have 
recently been exposed to third-generation cephalosporin 
antibiotics. This applies especially to patients who did 
not receive appropriate antibiotics within 48 hours of 
presentation, who had a higher risk of a fatal outcome. 
Other antibiotics that may be useful include gentamicin, 
for which the resistant rate was only 9.5%. This may be 
related to the infrequent use of gentamicin in the study 
unit. Although ciprofloxacin also showed good activity 
against the K. pneumoniae isolates (87% susceptibility 
rate), it cannot be recommended for routine use in pedi- 
atric patients, in view of its potential harmful effects on 
bone and cartilage growth. 
It is important to note that ESBLs may be overlooked 
in routine testing and, therefore, microbiologists may 
grossly underestimate their prevalence. A variety of 
maneuvers have been used to improve the identification 
of bacteria-producing ESBL, including testing with larger- 
than-normal inocula, lower breakpoints for resistance, 
and in vitro tests for synergy between B-lactams and 
B-lactamase inhibitors. 16,17 The availability of DNA finger- 
printing allows molecular epidemiologic data to be 
obtained and is especially useful during outbreaks. 
Although it is accepted that total eradication of an 
ESBL-producing strain is not a realistic goal once it is 
established in a ward or hospital, efforts should be made 
to reduce its incidence. This may be achieved with judi- 
cious use of antibiotics and manipulation of empirical 
antibiotic policies; in this case, for the treatment of febrile 
neutropenia, the strategy involved continuous surveil- 
lance of local bacteriologic patterns. With cure rates of 
certain cancers approaching 70 to SO%, it is tragic to lose 
such patients to infection. 
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